These 3D renderings of mouse skulls clearly show the effects of RUNX2 deficiency. Fgfr3-creER mice, which were the control group, and Fgfr3-Runx2c ...

FGFR3 is a clinically validated target in oncology, with one small molecule inhibitor (erdafitinib) approved. There are no FGFR3 ADCs beyond BHV-1530 advanced in clinical testing.

Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad ...

Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data ...

Fibroblast growth factor receptors (FGFRs; FGFR1, FGFR2, FGFR3, FGFR4) are frequently mutated oncogenes in solid cancers. The oncogenic potential of FGFR rearrangements and few hotspot point mutations ...

DataM Intelligence | competitive Intelligence Achondroplasia drug market sees rising competition, with weekly and oral treatments targeting ...

For TransCon CNP treatment-naïve children, mean annualized growth velocity (AGV) was 9.14 cm/year, representing an increase from baseline at Week 26 of 4.23 cm/year, with an improvement in mean ACH ...

Achondroplasia is a genetic condition resulting from a mutation in the FGFR3 gene. It affects bone growth, resulting in short stature and distinctive physical features.